- Home
- MFIN vs XBIT Comparison
MFIN vs XBIT Comparison
Compare MFIN & XBIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MFIN | XBIT |
|---|---|---|
| Founded | 1995 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Pharmaceuticals and Biotechnology |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 233.3M | 73.2M |
| IPO Year | 1996 | 2015 |
Fundamental Metrics
Financial Performance| Metric | MFIN | XBIT |
|---|---|---|
| Price | $10.65 | $2.44 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $12.00 | N/A |
| AVG Volume (30 Days) | 44.0K | ★ 73.6K |
| Earning Date | 10-29-2025 | 11-12-2025 |
| Dividend Yield | ★ 4.57% | N/A |
| EPS Growth | ★ 1.06 | N/A |
| EPS | ★ 1.71 | N/A |
| Revenue | ★ $338,783,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.83 | N/A |
| P/E Ratio | $6.15 | ★ N/A |
| Revenue Growth | ★ 15.53 | N/A |
| 52 Week Low | $7.71 | $2.09 |
| 52 Week High | $10.98 | $7.24 |
Technical Indicators
Market Signals| Indicator | MFIN | XBIT |
|---|---|---|
| Relative Strength Index (RSI) | 60.67 | 48.15 |
| Support Level | $9.96 | $2.15 |
| Resistance Level | $10.39 | $2.65 |
| Average True Range (ATR) | 0.31 | 0.15 |
| MACD | 0.08 | 0.02 |
| Stochastic Oscillator | 87.87 | 33.33 |
Price Performance
Historical ComparisonAbout MFIN Medallion Financial Corp.
Medallion Financial Corp is a finance company that originates and services loans in various industries. The five operating segments are, (1) recreation, (2) home improvement, (3) commercial, (4) taxi medallion, and (5) strategic partnership loans. The company generates maximum revenue from the Recreation segment.
About XBIT XBiotech Inc.
XBiotech Inc is a United States-based clinical-stage biopharmaceutical company. The company is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing Anti-inflammatory therapeutic antibodies as a treatment for cancer. Geographically, all of its operations are in the United States.